Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Addressing Social Determinants of Health in Hidradenitis Suppurativa Care
Panelist discusses how social determinants of health create significant diagnostic barriers for hidradenitis suppurativa through systemic inequities, limited health care access, and provider knowledge gaps. Health systems can mitigate these challenges through targeted educational, technological, and culturally responsive interventions.
EP: 1.Bridging the Gap in Recognizing Early Symptoms of Hidradenitis Suppurativa
EP: 2.Improving HS Diagnosis and Care Through Better Alignment of Staging and Severity
Now Viewing
EP: 3.Addressing Social Determinants of Health in Hidradenitis Suppurativa Care
EP: 4.Economic Implications of Diagnostic Delays in Hidradenitis Suppurativa
EP: 5.Strategies for Equitable Access in Hidradenitis Suppurativa
EP: 6.Partnering With Patient Advocacy Groups to Improve HS Awareness and Outcomes
EP: 7.Holistic Care for HS Patients: The Power of Multidisciplinary Models
EP: 8.The Case for HS Centers of Excellence: Evidence for Improved Patient Outcomes
EP: 9.Innovating HS Care: Applying Multidisciplinary Lessons to Diagnosis and Management
EP: 10.The Value Proposition: Justifying the Investment in HS Centers of Excellence
EP: 11.Key Takeaways on HS Care: Multidisciplinary Collaboration and Equity Solutions
EP: 12.Navigating HS Management: The Patient Journey
EP: 13.Advancing HS Outcomes: Resource Prioritization and Success Measurement
EP: 14.Tailoring HS Treatment: The Path to Better Patient Outcomes
Video content above is prompted by the following:
- How do social determinants of health create barriers to timely and accurate diagnosis of HS?
- What strategies can health systems implement to mitigate these barriers?
Related Content
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Article
Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More
